Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650219 | 0.86 | GRIA1 (0.47) | CYP3A4NAMPTXDHGRIA1GRIA2 | |
| SCHEMBL406467 | 0.70 | MAPT (0.50) | CYP3A4NAMPTXDHGRIA1GRIA2 | |
| SCHEMBL6008297 | 0.67 | PARP1 (0.73) | CYP3A4NAMPTXDHGRIA1GRIA2 | |
| SCHEMBL29993384 | 0.67 | PARP1 (0.73) | CYP3A4NAMPTXDHGRIA1GRIA2 | |
| SCHEMBL208707 | 0.67 | AHR (0.42) | DAO | |
| SCHEMBL207535 | 0.67 | AHR (0.42) | NOS1ALDH1A1 | |
| SCHEMBL2955170 | 0.67 | TYR (0.42) | CYP3A4LMNAALOX15ALDH1A1TSHR | |
| SCHEMBL30011 | 0.67 | MAPT (0.54) | CYP3A4NAMPTXDHGRIA1GRIA2 | |
| SCHEMBL29904251 | 0.67 | MAPT (0.54) | CYP3A4NAMPTXDHGRIA1GRIA2 | |
| SCHEMBL4427396 | 0.66 | GRIA1 (0.58) | CYP3A4GRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123993-A1 | SELECTIVE APOPTOSIS-INDUCING METHODS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-111849912-B | Method for activating T cells using inducible chimeric polypeptides | 贝里坤制药股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117402829-A | Dual control for therapeutic cell activation or elimination | 贝里坤制药股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-11839647-B2 | Methods for inducing partial apoptosis using caspase polypeptides | BELLICUM PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230270831-A1 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | BAYLOR COLLEGE OF MEDICINE | 2023-08-31 | — | — | US | disclosed |
| EP-4219544-A1 | T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum (NL) | 2023-08-02 | — | — | EP | disclosed |
| EP-4201955-A1 | T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum (NL) | 2023-06-28 | — | — | EP | disclosed |
| US-20230065562-A1 | DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-03-02 | — | — | US | disclosed |
| EP-3268014-B1 | T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | ACADEMISCH ZIEKENHUIS LEIDEN H O D N LEIDS UNIV MEDISCH CENTRUM (NL) | 2022-09-21 | — | — | EP | disclosed |
| US-20220152100-A1 | METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-05-19 | — | — | US | disclosed |
| US-20080213891-A1 | RNAi Agents Comprising Universal Nucleobases | ALNYLAM PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| EP-1951737-A2 | RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION | Alnylam Pharmaceuticals Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1913011-A2 | OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | Alnylam Pharmaceuticals Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1828215-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | Alnylam Pharmaceuticals Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070197460-A1 | RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2007053696-A2 | RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2006112872-A2 | OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006093526-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213891-A1 | RNAi Agents Comprising Universal Nucleobases | NOP2, NOP58, FBL | CYP3A4 4505/4885NAMPT 827/4885XDH 3628/4885 |
| US-20070197460-A1 | RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION | SNRPE, EIF2AK2, AGO2 | CYP3A4 4767/4885NAMPT 824/4885XDH 3439/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | CYP3A4 3893/4885NAMPT 113/4885XDH 2553/4885 |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | NT5C3B, DERA, DUT | CYP3A4 4661/4885NAMPT 35/4885XDH 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.